Author: Al-Jighefee, Hadeel T.; Najjar, Hoda; Ahmed, Muna Nizar; Qush, Abeer; Awwad, Sara; Kamareddine, Layla
Title: COVID-19 Vaccine Platforms: Challenges and Safety Contemplations Cord-id: n1nwzj1x Document date: 2021_10_18
ID: n1nwzj1x
Snippet: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a pandemic as of March 2020, creating a global crisis and claiming millions of lives. To halt the pandemic and alleviate its impact on society, economy, and public health, the development of vaccines and antiviral agents against SARS-CoV-2 was a dire need. To date, various platforms have been utilized for SARS-CoV-2 vaccine development, and over 200 vaccine candidates have been produced, many of which have obtained the U
Document: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a pandemic as of March 2020, creating a global crisis and claiming millions of lives. To halt the pandemic and alleviate its impact on society, economy, and public health, the development of vaccines and antiviral agents against SARS-CoV-2 was a dire need. To date, various platforms have been utilized for SARS-CoV-2 vaccine development, and over 200 vaccine candidates have been produced, many of which have obtained the United States Food and Drug Administration (FDA) approval for emergency use. Despite this successful development and licensure, concerns regarding the safety and efficacy of these vaccines have arisen, given the unprecedented speed of vaccine development and the newly emerging SARS-CoV-2 strains and variants. In this review, we summarize the different platforms used for Coronavirus Disease 2019 (COVID-19) vaccine development, discuss their strengths and limitations, and highlight the major safety concerns and potential risks associated with each vaccine type.
Search related documents:
Co phrase search for related documents- acute sars cov respiratory syndrome coronavirus and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65
- acute sars cov respiratory syndrome coronavirus and adaptive immune response innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- acute sars cov respiratory syndrome coronavirus and additional vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- acute sars cov respiratory syndrome coronavirus and adenovirus immunity: 1, 2
- acute sars cov respiratory syndrome coronavirus and adenovirus vaccinia: 1
- acute sars cov respiratory syndrome coronavirus and adjuvant activity: 1, 2
- acute sars cov respiratory syndrome coronavirus and live attenuated vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- acute sars cov respiratory syndrome coronavirus and live virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- acute sars cov respiratory syndrome coronavirus and lnp lipid nanoparticle: 1, 2, 3, 4, 5, 6
- acute sars cov respiratory syndrome coronavirus and loaded virus: 1
- acute sars cov respiratory syndrome coronavirus and low efficacy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- acute sars cov respiratory syndrome coronavirus and low immunogenicity: 1, 2, 3, 4, 5, 6, 7, 8, 9
- acute sars cov respiratory syndrome coronavirus and lung pathology: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68
- adaptive immune response and adenovirus immunity: 1
- adaptive immune response and adjuvant activity: 1, 2, 3, 4
- adaptive immune response and live attenuated vaccine: 1, 2
- adaptive immune response and live virus: 1, 2, 3
- adaptive immune response and lnp lipid nanoparticle: 1, 2
- adaptive immune response and lung pathology: 1, 2, 3, 4
Co phrase search for related documents, hyperlinks ordered by date